BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-405@pharmaconomics
DTSTAMP:20260707T034217Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:EXEL PDUFA — zanzalintinib
DESCRIPTION:The FDA's approval decision on zanzalintinib for previously treated metastatic colorectal cancer is due Dec 3\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel20260331exhibit991.htm\n\nTrack it: https://www.pharmaconomics.com/e/405
URL:https://www.pharmaconomics.com/e/405
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:EXEL catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR